Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of boronic acids and 2,4-disubstituted thiazoles. It contains a thiazole ring and a boronic acid moiety. It acts as an inhibitor of beta-lactamase TEM enzymes, which are bacterial enzymes responsible for antibiotic resistance by hydrolyzing beta-lactam antibiotics. By inhibiting these enzymes, it can potentially restore the efficacy of beta-lactam antibiotics against resistant bacteria. The compound is experimental and has not been approved for clinical use or indicated for any specific conditions. Its molecular formula is C7H11BN4O4S with an average molecular weight of approximately 258 Da[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [(2-amino-alpha-methoxyimino-4-thiazolylacetyl)amino]methylboronic acid.